![Max Herrmann](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Max Herrmann
Keine laufenden Positionen mehr
Vermögen: 36 589 $ am 31.05.2026
Profil
Mr. Max Herrmann was previously employed as an Analyst by Stifel Nicolaus Europe Ltd., an Analyst by Oriel Securities Ltd., a Chief Financial Officer & Secretary by Silence Therapeutics Plc, a Chief Financial Officer by Regenerative Medicine Assets Ltd., a Research Analyst by ING Bank NV (United Kingdom), a Managing Director & Head-European Pharmaceutical by ING Groep NV, and a Financial Controller by Onyx Pharmaceuticals, Inc. He also served on the board at Axordia Ltd., Intercytex Ltd. and Regenerative Medicine Assets Ltd.
He received his undergraduate degree from the University of Kent.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
Foresight Enterprise VCT Plc
 Foresight Enterprise VCT Plc Investment ManagersFinance Functions as a private equity fund 0,01 % | 01.12.2025 | 58.000 ( 0,01 % ) | 36 589 $ | 31.05.2026 |
Ehemalige bekannte Positionen von Max Herrmann
| Unternehmen | Position | Ende |
|---|---|---|
Stifel Nicolaus Europe Ltd.
 Stifel Nicolaus Europe Ltd. Investment Banks/BrokersFinance Provides brokerage services | Analyst-Equity | 01.07.2024 |
Oriel Securities Ltd.
 Oriel Securities Ltd. Investment Banks/BrokersFinance Provides independent, corporate, and institutional stockbroking | Analyst-Equity | 01.02.2015 |
Axordia Ltd.
 Axordia Ltd. Miscellaneous Commercial ServicesCommercial Services Develops therapies derived from human embryonic stem cells | Direktor/Vorstandsmitglied | 18.04.2013 |
| SILENCE THERAPEUTICS PLC | Finanzdirektor/CFO | 02.08.2012 |
ING Bank NV (United Kingdom)
 ING Bank NV (United Kingdom) Investment Banks/BrokersFinance Provides brokerage services | Analyst-Equity | 01.06.2007 |
Ausbildung von Max Herrmann
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
78
Beziehungen ersten Grades
10
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 10 |
|---|---|
Onyx Pharmaceuticals, Inc.
 Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that provide therapeutics for cancer | Health Technology |
ING Bank NV (United Kingdom)
ING Bank NV (United Kingdom) Investment Banks/BrokersFinance Provides brokerage services | Finance |
ING Groep NV
 ING Groep NV Major BanksFinance Provides retail and wholesale banking services | Finance |
Regenerative Medicine Assets Ltd.
 Regenerative Medicine Assets Ltd. Pharmaceuticals: MajorHealth Technology Engages in healthcare industry | Health Technology |
Silence Therapeutics Plc
 Silence Therapeutics Plc Miscellaneous Commercial ServicesCommercial Services Engages in the research and development of novel pharmaceutical products | Commercial Services |
Intercytex Ltd.
 Intercytex Ltd. Pharmaceuticals: MajorHealth Technology Develops regenerative medicines | Health Technology |
Oriel Securities Ltd.
Oriel Securities Ltd. Investment Banks/BrokersFinance Provides independent, corporate, and institutional stockbroking | Finance |
Axordia Ltd.
Axordia Ltd. Miscellaneous Commercial ServicesCommercial Services Develops therapies derived from human embryonic stem cells | Commercial Services |
University of Kent
 University of Kent Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Stifel Nicolaus Europe Ltd.
Stifel Nicolaus Europe Ltd. Investment Banks/BrokersFinance Provides brokerage services | Finance |
